Drs Steven Feldman and Tina Bhutani-Jacques explore how next-generation oral therapies are closing the gap with biologics and reshaping psoriasis care. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/ca8/p04/podcast-psoriasis-s4-ep2-2026a10006a5. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Acitretin Revisited in the Era of Biologics https://pubmed.ncbi.nlm.nih.gov/20673152/ Apremilast in Psoriasis: Current Landscape and Perspectives https://pubmed.ncbi.nlm.nih.gov/40739686/ Deucravacitinib Versus Placebo and Apremilast in Moderate-to-Severe Plaque Psoriasis: Efficacy and Safety Results From the 52-Week, Randomized, Double-Blinded, Placebo-Controlled Phase 3 POETYK PSO-1 Trial https://pubmed.ncbi.nlm.nih.gov/35820547/ Apremilast Prescribing Information https://www.pi.amgen.com/-/media/Project/Amgen/Repository/pi-amgen-com/Otezla/otezla_pi_english.pdf Deucravacitinib Prescribing Information https://packageinserts.bms.com/pi/pi_sotyktu.pdf Tyrosine Kinase 2 Inhibition With Zasocitinib (TAK-279) in Psoriasis: A Randomized Clinical Trial https://pubmed.ncbi.nlm.nih.gov/39167366/ Emerging Oral Therapies for the Treatment of Psoriasis: A Review of Pipeline Agents https://pubmed.ncbi.nlm.nih.gov/38258121/ Oral Icotrokinra for Plaque Psoriasis in Adults and Adolescents https://pubmed.ncbi.nlm.nih.gov/41191940/ National Psoriasis Foundation https://www.psoriasis.org/ Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.